Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Peripheral T-cell lymphomas (PTCLs) are aggressive non-Hodgkin lymphomas with high relapse rates.
• PTCL not otherwise specified (PTCL-NOS) is the most common and challenging subtype.
• Accurate diagnosis relies on integrated molecular, histopathological, and immunophenotypic analyses.

Observation:

• A patient with PTCL-NOS experienced disease progression despite conventional (CHOP regimen) and novel therapies.
• Genetic analysis revealed a TET2 mutation in the patient's tumor.
• The patient was subsequently treated with azacitidine, an epigenetic modifying agent.

Findings:

• Azacitidine treatment led to a favorable clinical response in the patient with PTCL-NOS and a TET2 mutation.
• This outcome suggests a potential role for azacitidine in refractory PTCL cases.
• The patient's response highlights the importance of molecular profiling for guiding therapy selection.

Implications:

• This case supports further investigation into azacitidine's efficacy for PTCL patients, particularly those with TET2 mutations.
• It underscores the potential of epigenetic therapies as a treatment strategy for relapsed or refractory PTCL.
• Personalized treatment approaches based on molecular targets may improve outcomes in aggressive lymphomas.